ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

WSJ BLOG/Health: New Caution Urged Over Sole Oral MS Drug On the Market

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.) The FDA says the only oral multiple-sclerosis drug on the market -- Novartis's Gilenya -- shouldn't be used in patients with a recent history of stroke or some heart problems. As WSJ reports, a safety review of the treatment was prompted by a report in November of a 59-year-old patient dying in the U.S. less than a day after taking the first dose of the drug. Although the agency said an exact cause of the patient's death couldn't be identified, it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the treatment can lower a person's heart rate temporarily. Patients who have had a stroke or heart trouble within the past six months shouldn't take the drug, the FDA says. It also shouldn't be used in patients taking some kinds of medicines to treat heart arrhythmias. The FDA warning comes after Europe's drug regulator last month requested stronger safety warnings. The U.S. agency is currently reviewing another oral MS drug from Biogen Idec designed to work through a different mechanism than Gilenya. -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com.

Stock News for Novartis (NVS)
DateTimeHeadline
04/24/201417:35:36ADR Shares End Mixed; Unilever, AstraZeneca Shares Active
04/24/201415:35:42U.S. Stocks Rise, Buoyed by Apple Results
04/24/201415:20:17Lilly Says Takeda May Not Cover Its Share of $9 Billion Lawsuit
04/24/201412:39:32Novartis Leads Zurich Stocks Lower
04/24/201412:37:47EUROPE MARKETS: European Stocks End Choppy Day In Black
04/24/201410:39:52EUROPE MARKETS: European Stocks Pare Gains On Ukraine Tensions
04/24/201408:00:28Zimmer to Buy Biomet for $13.35 Billion -- Update
04/24/201406:18:32EUROPE MARKETS: European Stocks Strong After Ifo, Draghi Comments
04/24/201404:30:12Novartis 1Q Profit Rises About 23%
04/24/201402:40:06Novartis 1st Quarter Profit Rises About 23%
04/24/201402:27:06Novartis First-Quarter Profit Rises About 23% -- Update
04/22/201413:06:07LONDON MARKETS: Glaxo, AstraZeneca Lead U.K. Stocks To Two-week...
04/22/201412:38:25EUROPE MARKETS: Drug Stocks Drive European Markets Higher
04/22/201412:35:06Novartis 1Q 2014 -- Forecast
04/22/201409:50:05Glaxo Exits Cancer Drugs
04/22/201409:44:35LONDON MARKETS: Glaxo, AstraZeneca Lead Gains In U.K. Stocks
04/22/201409:34:59U.S. Stock Futures Trade Flat
04/22/201408:32:05Novartis Overhauls Portfolio With Deals Worth $25 Billion...
04/22/201405:51:23Novartis Overhauls Portfolio With Deals Worth $25 Billion...
04/22/201404:40:14European Stocks Start Strongly After Easter Holiday

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad